Inovio Pharmaceuticals

Yahoo Finance • 3 days ago

DEADLINE ALERT for TCPC, ORCL, PSFE, and INO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the... Full story

Yahoo Finance • 3 days ago

Bronstein, Gewirtz & Grossman LLC Urges Inovio Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and... Full story

Yahoo Finance • 5 days ago

INOVIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inovio (INO) To Contact Him Directly To Discuss Their Options If you purchased or acquired Inovio securities between October 10, 202... Full story

Yahoo Finance • 6 days ago

Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 7, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or o... Full story

Yahoo Finance • 7 days ago

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INO

NEW YORK, Feb. 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive... Full story

Yahoo Finance • 9 days ago

INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (“Inovio” or “the Company”) (NASDAQ: INO)... Full story

Yahoo Finance • 10 days ago

Portnoy Law Firm Announces Class Action on Behalf of Inovio Pharmaceuticals, Inc. Investors

LOS ANGELES, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Inovio Pharmaceuticals, Inc., (“Inovio” or the "Company") (NASDAQ: INO) investors of a class action on behalf of investors that bought securities between October... Full story

Yahoo Finance • 10 days ago

INO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 1... Full story

Yahoo Finance • 13 days ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INO

NEW YORK, Feb. 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10,... Full story

Yahoo Finance • 15 days ago

ROSEN, A LEADING LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INO

NEW YORK, Feb. 14, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10,... Full story

Yahoo Finance • 16 days ago

INO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Inovio Pharmaceuticals, Inc. Class Action

SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between Octob... Full story

Yahoo Finance • 20 days ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. (INO)

NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons o... Full story

Yahoo Finance • 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at... Full story

Yahoo Finance • 2 months ago

Inovio drops as respiratory papillomatosis asset denied accelerated review

[FDA headquarters in Washington DC.] JHVEPhoto * Inovio is down ~21% Monday after the US FDA accepted its BLA for INO-3107 for recurrent respiratory papillomatosis, but with a standard review timeline. * The company had filed the appl... Full story

Yahoo Finance • 2 months ago

FDA Accepts INOVIO's BLA For INO-3107 In Recurrent Respiratory Papillomatosis

(RTTNews) - Inovio Pharmaceuticals, Inc. (INO) announced that its Biologics License Application for INO-3107, proposed for the treatment of adults with recurrent respiratory papillomatosis, has been accepted for review by the FDA. The U.S... Full story

Yahoo Finance • 4 months ago

Inovio outlines mid-2026 launch for INO-3107 as BLA submission progresses

Earnings Call Insights: Inovio Pharmaceuticals (INO) Q3 2025 MANAGEMENT VIEW * CEO Jacqueline Shea highlighted, “we have achieved our primary objective for this year, which is completing the rolling submission of our BLA for INO-3107.... Full story

Yahoo Finance • 4 months ago

Inovio Pharmaceuticals Q3 2025 Earnings Preview

* Inovio Pharmaceuticals (INO [https://seekingalpha.com/symbol/INO]) is scheduled to announce Q3 earnings results on Monday, November 10th, after market close. * The consensus EPS Estimate is -$0.48 [https://seekingalpha.com/symbol/INO... Full story

Yahoo Finance • 6 months ago

Inovio says FDA agrees with rolling BLA submission for rare disease asset

[FDA Headquarters] * The U.S. FDA is in agreement with Inovio Pharmaceuticals (NASDAQ:INO [https://seekingalpha.com/symbol/INO]) regarding its rolling BLA submission plan for INO-3107 for Recurrent Respiratory Papillomatosis. * The ph... Full story

Yahoo Finance • 6 months ago

Oppenheimer maintains Outperform rating on Inovio stock amid FDA approval for competitor

Investing.com - Oppenheimer has reiterated an Outperform rating and $13.00 price target on Inovio Pharmaceuticals (NASDAQ:INO) following the FDA approval of a competing therapy for recurrent respiratory papillomatosis (RRP). According to I... Full story

Yahoo Finance • 7 months ago

Gapping stocks in Friday's session

Let's have a look at the gap up and gap down stocks in today's session. [gap] GAP UP STOCKS TICKER CHANGE COMMENT PMNT [https://www.chartmill.com/stock/quote/PMNT/profile] 88.98% PERFECT MOMENT LTD'S (NYSEARCA:PMNT [https... Full story